Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial

Hepion Pharmaceuticals Inc HEPA has announced additional efficacy data from its Phase 2a AMBITION clinical trial.
Related Content: Hepion Pharma's NASH Candidate Aces Mid-Stage Study.
The 43-subject trial was designed to investigate CRV431 at doses of 75 mg (n=12), and 225 mg (n=17) administered as soft gelatin capsules to presumed F2 and F3 NASH subjects for 28 days, followed by a 14-day observation period for safety.
Hepion reported additional data on biomarkers, alanine aminotransferase (ALT) and N-terminal type III collagen pro-peptide (Pro-C3), and pharmacologic and bioinformatic analyses.
Once-daily 225 mg dosing of CRV431 decreased mean Pro-C3 levels by 7.9% and 22.4% (-11.6 ng/ml) at days 28 and 42, respectively, compared to 3.5% and 4.7% reduction with placebo.
CRV431 treatment produced changes in gene expression that were consistent with antifibrotic effects.
Stephen Harrison, MD, will present the full AMBITION analysis at the upcoming AASLD "The Liver Meeting" in early November 2021.
Price Action: HEPA shares are up 1.81% at $1.69 during the market session on the last check Monday.